Press Releases

Sign up for Email Alerts Press Release RSS

08/27/2019
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Term:Corporate/Financial News
Language:English
08/26/2019
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
Term:Corporate/Financial News
Language:English
08/01/2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Term:Partnering News
Language:English
07/29/2019
Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
Term:Corporate/Financial News
Language:English
07/26/2019
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Term:Corporate/Financial News
Language:English
07/25/2019
Bristol-Myers Squibb Reports Second Quarter Financial Results
Term:Corporate/Financial News
Language:English
07/24/2019
Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227
Term:R&D News
Language:English
07/24/2019
Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
Term:R&D News
Language:English
07/18/2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer
Term:Partnering News
Language:English
07/01/2019
Bristol-Myers Squibb Completes Divestment of UPSA
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm